In this article, we will discuss the 10 Best Growth Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates.
Strong earnings growth has underscored the need to focus on growth stocks amid an equity market battered by monetary policy uncertainties, surging inflation, and unending geopolitical tensions. Earnings growth is expected to remain robust for the better part of the year, with FactSet projecting 23% for the full year.
Investors looking past the stalemate in the US-Iran war have once again affirmed the case for growth stocks despite the premium valuations in play. While some yellow flags have emerged, the stock market remains in an uptrend, according to Goldman Sachs strategists.
“The conditions that have marked the ends of high-valuation, high-concentration bull markets in the past remain mostly absent today, although some of those conditions appear to be drawing closer,” wrote a team of Goldman Sachs equity analysts in a Tuesday note
Amid the valuation concerns with equities near all-time highs, growth stocks continue to outperform value stocks. The S&P 500 Growth index is up about 9% year to date, compared to a 6% gain for value stocks in the index.
Although Billionaire investor Ray Dalio has warned of a potential artificial intelligence bubble, his portfolio at Bridgewater Associates boasts significant exposure to growth stocks that are also big players in AI. In the first quarter, Dalio was adding to some of the big names, expecting them to deliver significant returns in the long run amid the AI revolution.
Ray Dalio of Bridgewater Associates
Our Methodology
To compile a list of the Best Growth Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates, we analyzed the hedge fund’s latest 13F filings. We focused on growth stocks that have grown sales by over 20% over the past five years and are poised to grow earnings by over 10% the next five years. We also detailed the number of hedge funds that hold stakes in the stocks in Q1 2026. Finally, we ranked the stocks in ascending order by Bridgewater Associates’ stake in each.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
Best Growth Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates
10. Agnico Eagle Mines Limited (NYSE:AEM)
Expected Five-Year Earnings Growth: 15.17%
Number of Hedge Fund Holders: 46
Bridgewater Associates Equity Stake: $18.01 Million
Agnico Eagle Mines Limited (NYSE:AEM) is one of the best growth stocks to buy, according to billionaire Ray Dalio’s Bridgewater Associates. On June 4, Agnico Eagle Mines Limited (NYSE:AEM) announced it is acquiring a 7.5% net profit interest royalty from Prism Resources.
The company is to pay $5 million in cash for the profit-interest royalty, which covers certain properties in the Porcupine Mining District of Ontario. While the transaction is expected to close in the third quarter, it requires approval from Prism shareholders and is subject to other customary closing conditions. Although Agnico Eagle Mines Limited owns about 5.75 million shares of Prism Resources, it is not acquiring any additional common shares through the new transaction.
The acquisition of the 7.5% net profit interest royalty comes on the heels of Agnico Eagle Mines entering into an investment agreement with Wallbridge Mining Company. The company is to purchase 243,927,966 common shares of Wallbridge at $0.092 per share for a total consideration of C$22.44 million. The acquisition is part of a strategy focused on securing strategic positions in prospective opportunities.
Agnico Eagle Mines Limited (NYSE:AEM) is a Canadian-based, senior gold mining company and the second-largest gold producer in the world. It is engaged in the exploration, development, and production of precious metals and operates a diverse portfolio of mines across Canada, Australia, Finland, and Mexico.
9. Eli Lilly and Company (NYSE:LLY)
Expected Five-Year Earnings Growth: 28.54%
Number of Hedge Fund Holders: 132
Bridgewater Associates Equity Stake: $65.13 Million
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy, according to billionaire Ray Dalio’s Bridgewater Associates. On June 10, the US Food and Drug Administration approved a new dosing regimen for Eli Lilly and Company (NYSE:LLY) in the treatment of patients with moderate to severe atopic dermatitis.
The new dosing regimen permits adults and children 12 years and older weighing at least 88 pounds to receive a single 250mg injection every 8 weeks. The drug was previously approved for monthly maintenance dosing. With the extended dosing regimen, patients can now better manage their condition with as few as 6 maintenance injections.
The FDA approved the new dosing regimen based on longitudinal exposure-response modeling data and clinical data from the 32-week Phase 3 Adjoin trial. Eli Lilly and Co. did not record any new safety signals in the trials, and no patients discontinued treatment due to adverse events.
EBGLYSS, a monoclonal antibody that targets IL-13, a cytokine involved in the inflammatory process of atopic dermatitis, was approved in the U.S., Japan, and Canada in 2024 and in the European Union in 2023.
Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical giant that develops, manufactures, and markets human medicines. They focus primarily on treating diseases in areas like cardiometabolic health, oncology, immunology, and neuroscience.
Hedge Fund Resource Center